[3H]Pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes

M. Watson, William R Roeske, H. I. Yamamura

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

Studies show [3H]PZ identified selectively a subpopulation of muscarinic binding sites compared to classical antagonists like (-)-[3H]QNB in many central and peripheral tissues. We characterized the binding and regulation of selected antagonists to high-affinity [3H]PZ (putative M1) and low-affinity PZ (putative M2) sites in rat cerebral cortex (predominantly M1) and heart (predominantly M2). Saturation isotherms of [3H]PZ and (-)-[3H]QNB were performed under various conditions. Guanyl-5'-yl-imidodiphosphate (30 μM) showed little effect on K(d) (dissociation constant) or total binding capacity (total receptor density) values. Higher ionic strength buffers yielded lower affinity values for [3H]PZ and (-)-[3H]QNB. Kinetic studies confirmed high affinity K(d) values seen in steady-state assays. We conducted inhibition studies of selected muscarinic antagonists including the reportedly cardioselective (putative M2) drug, AF-DX 116 {11-[(2-diethylamino)methyl-1-piperidinyl)-acetyl]-5, 11-dihydro-6H-pyrido(2,3-b)(1,4)-benzodiazepine-6-one}, the reportedly M1 selective compound, PZ, and the classical antagonist (-)QNB, using [3H]PZ and (-)-[3H]QNB-labeled cerebral cortical and cardiac homogenates. Assays were done with and without guanyl-5'-yl imidophosphate at 25°C in 10 mM Na-K-phosphate, 50 mM Na-K-phosphate and modified Krebs-phosphate buffer. Studies showed antagonists generally had higher affinity in 10 mM Na-K-phosphate buffer, were insensitive to guanyl-5'-yl imidodiphosphate and had Hill values (n(H) nearly equal to one. Cardiac PZ/[3H]QNB curves were steep. Whereas cortical PZ/[3H]PZ inhibition curves were also steep, PZ/(-)-[3H]QNB and AF-DX 116/(-)-[3H]QNB curves had n(H) < 1 and were better fit to a 2-site model. AF-DX 116 had a selectivity profile inverse to PZs. Thus, direct and indirect studies show PZ, unlike (-)-QNB, discriminates high- and low-affinity (putative M1 and M2) sites in each of our assay conditions in these membranes. Many antagonists were M1 selective. Only AF-DX 116 was putative M2 selective. Orders of affinity and selectivity for muscarinic antagonists support the concept of pharmacologically distinct (putative M1 and M2) muscarinic receptor subtypes.

Original languageEnglish (US)
Pages (from-to)419-427
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume237
Issue number2
StatePublished - 1986

Fingerprint

Quinuclidinyl Benzilate
Pirenzepine
Cholinergic Agents
Phosphates
Guanylyl Imidodiphosphate
Buffers
Muscarinic Antagonists
Muscarinic M2 Receptors
Muscarinic M1 Receptors
Cerebral Cortex
Osmolar Concentration
Binding Sites
otenzepad
Membranes
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

@article{fae9a65a3b38430e84a9bbf134d63274,
title = "[3H]Pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes",
abstract = "Studies show [3H]PZ identified selectively a subpopulation of muscarinic binding sites compared to classical antagonists like (-)-[3H]QNB in many central and peripheral tissues. We characterized the binding and regulation of selected antagonists to high-affinity [3H]PZ (putative M1) and low-affinity PZ (putative M2) sites in rat cerebral cortex (predominantly M1) and heart (predominantly M2). Saturation isotherms of [3H]PZ and (-)-[3H]QNB were performed under various conditions. Guanyl-5'-yl-imidodiphosphate (30 μM) showed little effect on K(d) (dissociation constant) or total binding capacity (total receptor density) values. Higher ionic strength buffers yielded lower affinity values for [3H]PZ and (-)-[3H]QNB. Kinetic studies confirmed high affinity K(d) values seen in steady-state assays. We conducted inhibition studies of selected muscarinic antagonists including the reportedly cardioselective (putative M2) drug, AF-DX 116 {11-[(2-diethylamino)methyl-1-piperidinyl)-acetyl]-5, 11-dihydro-6H-pyrido(2,3-b)(1,4)-benzodiazepine-6-one}, the reportedly M1 selective compound, PZ, and the classical antagonist (-)QNB, using [3H]PZ and (-)-[3H]QNB-labeled cerebral cortical and cardiac homogenates. Assays were done with and without guanyl-5'-yl imidophosphate at 25°C in 10 mM Na-K-phosphate, 50 mM Na-K-phosphate and modified Krebs-phosphate buffer. Studies showed antagonists generally had higher affinity in 10 mM Na-K-phosphate buffer, were insensitive to guanyl-5'-yl imidodiphosphate and had Hill values (n(H) nearly equal to one. Cardiac PZ/[3H]QNB curves were steep. Whereas cortical PZ/[3H]PZ inhibition curves were also steep, PZ/(-)-[3H]QNB and AF-DX 116/(-)-[3H]QNB curves had n(H) < 1 and were better fit to a 2-site model. AF-DX 116 had a selectivity profile inverse to PZs. Thus, direct and indirect studies show PZ, unlike (-)-QNB, discriminates high- and low-affinity (putative M1 and M2) sites in each of our assay conditions in these membranes. Many antagonists were M1 selective. Only AF-DX 116 was putative M2 selective. Orders of affinity and selectivity for muscarinic antagonists support the concept of pharmacologically distinct (putative M1 and M2) muscarinic receptor subtypes.",
author = "M. Watson and Roeske, {William R} and Yamamura, {H. I.}",
year = "1986",
language = "English (US)",
volume = "237",
pages = "419--427",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - [3H]Pirenzepine and (-)-[3H]quinuclidinyl benzilate binding to rat cerebral cortical and cardiac muscarinic cholinergic sites. II. Characterization and regulation of antagonist binding to putative muscarinic subtypes

AU - Watson, M.

AU - Roeske, William R

AU - Yamamura, H. I.

PY - 1986

Y1 - 1986

N2 - Studies show [3H]PZ identified selectively a subpopulation of muscarinic binding sites compared to classical antagonists like (-)-[3H]QNB in many central and peripheral tissues. We characterized the binding and regulation of selected antagonists to high-affinity [3H]PZ (putative M1) and low-affinity PZ (putative M2) sites in rat cerebral cortex (predominantly M1) and heart (predominantly M2). Saturation isotherms of [3H]PZ and (-)-[3H]QNB were performed under various conditions. Guanyl-5'-yl-imidodiphosphate (30 μM) showed little effect on K(d) (dissociation constant) or total binding capacity (total receptor density) values. Higher ionic strength buffers yielded lower affinity values for [3H]PZ and (-)-[3H]QNB. Kinetic studies confirmed high affinity K(d) values seen in steady-state assays. We conducted inhibition studies of selected muscarinic antagonists including the reportedly cardioselective (putative M2) drug, AF-DX 116 {11-[(2-diethylamino)methyl-1-piperidinyl)-acetyl]-5, 11-dihydro-6H-pyrido(2,3-b)(1,4)-benzodiazepine-6-one}, the reportedly M1 selective compound, PZ, and the classical antagonist (-)QNB, using [3H]PZ and (-)-[3H]QNB-labeled cerebral cortical and cardiac homogenates. Assays were done with and without guanyl-5'-yl imidophosphate at 25°C in 10 mM Na-K-phosphate, 50 mM Na-K-phosphate and modified Krebs-phosphate buffer. Studies showed antagonists generally had higher affinity in 10 mM Na-K-phosphate buffer, were insensitive to guanyl-5'-yl imidodiphosphate and had Hill values (n(H) nearly equal to one. Cardiac PZ/[3H]QNB curves were steep. Whereas cortical PZ/[3H]PZ inhibition curves were also steep, PZ/(-)-[3H]QNB and AF-DX 116/(-)-[3H]QNB curves had n(H) < 1 and were better fit to a 2-site model. AF-DX 116 had a selectivity profile inverse to PZs. Thus, direct and indirect studies show PZ, unlike (-)-QNB, discriminates high- and low-affinity (putative M1 and M2) sites in each of our assay conditions in these membranes. Many antagonists were M1 selective. Only AF-DX 116 was putative M2 selective. Orders of affinity and selectivity for muscarinic antagonists support the concept of pharmacologically distinct (putative M1 and M2) muscarinic receptor subtypes.

AB - Studies show [3H]PZ identified selectively a subpopulation of muscarinic binding sites compared to classical antagonists like (-)-[3H]QNB in many central and peripheral tissues. We characterized the binding and regulation of selected antagonists to high-affinity [3H]PZ (putative M1) and low-affinity PZ (putative M2) sites in rat cerebral cortex (predominantly M1) and heart (predominantly M2). Saturation isotherms of [3H]PZ and (-)-[3H]QNB were performed under various conditions. Guanyl-5'-yl-imidodiphosphate (30 μM) showed little effect on K(d) (dissociation constant) or total binding capacity (total receptor density) values. Higher ionic strength buffers yielded lower affinity values for [3H]PZ and (-)-[3H]QNB. Kinetic studies confirmed high affinity K(d) values seen in steady-state assays. We conducted inhibition studies of selected muscarinic antagonists including the reportedly cardioselective (putative M2) drug, AF-DX 116 {11-[(2-diethylamino)methyl-1-piperidinyl)-acetyl]-5, 11-dihydro-6H-pyrido(2,3-b)(1,4)-benzodiazepine-6-one}, the reportedly M1 selective compound, PZ, and the classical antagonist (-)QNB, using [3H]PZ and (-)-[3H]QNB-labeled cerebral cortical and cardiac homogenates. Assays were done with and without guanyl-5'-yl imidophosphate at 25°C in 10 mM Na-K-phosphate, 50 mM Na-K-phosphate and modified Krebs-phosphate buffer. Studies showed antagonists generally had higher affinity in 10 mM Na-K-phosphate buffer, were insensitive to guanyl-5'-yl imidodiphosphate and had Hill values (n(H) nearly equal to one. Cardiac PZ/[3H]QNB curves were steep. Whereas cortical PZ/[3H]PZ inhibition curves were also steep, PZ/(-)-[3H]QNB and AF-DX 116/(-)-[3H]QNB curves had n(H) < 1 and were better fit to a 2-site model. AF-DX 116 had a selectivity profile inverse to PZs. Thus, direct and indirect studies show PZ, unlike (-)-QNB, discriminates high- and low-affinity (putative M1 and M2) sites in each of our assay conditions in these membranes. Many antagonists were M1 selective. Only AF-DX 116 was putative M2 selective. Orders of affinity and selectivity for muscarinic antagonists support the concept of pharmacologically distinct (putative M1 and M2) muscarinic receptor subtypes.

UR - http://www.scopus.com/inward/record.url?scp=0022560526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022560526&partnerID=8YFLogxK

M3 - Article

VL - 237

SP - 419

EP - 427

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 2

ER -